111 related articles for article (PubMed ID: 2403582)
1. Minimal residual disease in leukemia: studies in an animal model for acute myelocytic leukemia (BNML).
Martens AC; van Bekkum DW; Hagenbeek A
Int J Cell Cloning; 1990 Jan; 8(1):27-38. PubMed ID: 2403582
[TBL] [Abstract][Full Text] [Related]
2. The BN acute myelocytic leukemia (BNML) (a rat model for studying human acute myelocytic leukemia (AML)).
Martens AC; Van Bekkum DW; Hagenbeek A
Leukemia; 1990 Apr; 4(4):241-57. PubMed ID: 2195239
[TBL] [Abstract][Full Text] [Related]
3. Detection of minimal disease in acute leukemia using flow cytometry: studies in a rat model for human acute leukemia.
Martens AC; Hagenbeek A
Cytometry; 1985 Jul; 6(4):342-7. PubMed ID: 3860369
[TBL] [Abstract][Full Text] [Related]
4. [Minimum residual leukemic cells in genetically marked brown Norway rat myelocytic leukemia model].
Yan Y; Martens AC; Van Bekkum DW
Zhonghua Zhong Liu Za Zhi; 1992 Nov; 14(6):414-7. PubMed ID: 1304472
[TBL] [Abstract][Full Text] [Related]
5. Quantitative studies on graft-versus-leukemia after allogeneic bone marrow transplantation in rat models for acute myelocytic and lymphocytic leukemia.
Kloosterman TC; Tielemans MJ; Martens AC; van Bekkum DW; Hagenbeek A
Bone Marrow Transplant; 1994 Jul; 14(1):15-22. PubMed ID: 7951103
[TBL] [Abstract][Full Text] [Related]
6. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
Al-Mawali A; Gillis D; Lewis I
Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
[TBL] [Abstract][Full Text] [Related]
7. Graft-versus-leukemia in rat MHC-mismatched bone marrow transplantation is merely an allogeneic effect.
Kloosterman TC; Martens AC; van Bekkum DW; Hagenbeek A
Bone Marrow Transplant; 1995 Apr; 15(4):583-90. PubMed ID: 7655385
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of acetyldinaline for treatment of minimal residual disease (MRD): preclinical studies in the BNML rat model for human acute myelocytic leukemia.
el-Beltagi HM; Martens AC; Dahab GM; Hagenbeek A
Leukemia; 1993 Nov; 7(11):1795-800. PubMed ID: 8231248
[TBL] [Abstract][Full Text] [Related]
9. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
Al-Mawali A; Gillis D; Lewis I
Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
[TBL] [Abstract][Full Text] [Related]
10. [Detection of minimal residual disease in patients with acute myeloid leukemia].
Gal'tseva IV; Savchenko VG; Kulikov SM; Parovichnikova EN; Miterev GIu; Maslova ER; Isaev VG
Ter Arkh; 2003; 75(7):8-14. PubMed ID: 12934474
[TBL] [Abstract][Full Text] [Related]
11. Bivariate flow karyotyping of acute myelocytic leukemia in the BNML rat model.
Arkesteijn GJ; Martens AC; Jonker RR; Hagemeijer A; Hagenbeek A
Cytometry; 1987 Nov; 8(6):618-24. PubMed ID: 3480794
[TBL] [Abstract][Full Text] [Related]
12. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
13. Retrovirus-mediated transfer and expression of marker genes in the BN rat acute myelocytic leukemia model for the study of minimal residual disease (MRD).
Yan Y; Martens AC; de Groot CJ; Hendrikx PJ; Valerio D; van Bekkum DW; Hagenbeek A
Leukemia; 1993 Jan; 7(1):131-9. PubMed ID: 8418372
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 therapy after allogeneic bone marrow transplantation for acute myelocytic leukemia: studies in a relevant rat model for AML.
Kloosterman TC; Martens AC; Osterwalder B; Hagenbeek A
Bone Marrow Transplant; 1994 Dec; 14(6):965-73. PubMed ID: 7711675
[TBL] [Abstract][Full Text] [Related]
15. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
Zelezníková T; Babusíková O
Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
[TBL] [Abstract][Full Text] [Related]
16. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of high-dose cyclophosphamide in combination with total-body irradiation in the treatment of acute myelocytic leukemia: studies in a relevant rat model.
Hagenbeek A; Martens AC
Cancer Res; 1983 Jan; 43(1):408-12. PubMed ID: 6336603
[TBL] [Abstract][Full Text] [Related]
18. Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden.
Feller N; Jansen-van der Weide MC; van der Pol MA; Westra GA; Ossenkoppele GJ; Schuurhuis GJ
Exp Hematol; 2005 Jan; 33(1):120-30. PubMed ID: 15661405
[TBL] [Abstract][Full Text] [Related]
19. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
[TBL] [Abstract][Full Text] [Related]
20. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
